Neogen Corporation

NEOG ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
Operating Activities
Net Income $63.1M $43.8M $36.6M $33.5M $28.2M $27.2M $22.5M $22.8M
Depreciation & Amortization $17.1M $14.7M $12.2M $10.6M $9.2M $7.4M $6.2M $5.3M
Depreciation $10.3M $8.8M $7.5M $6.3M $5.4M $4.4M $3.6M $3.2M
Amortization $6.7M $5.9M $5.9M $4.3M $3.8M $3.0M $2.5M $2.1M
Stock-Based Compensation $4.9M $5.3M $5.5M $4.5M $3.7M $3.1M $2.5M $2.2M
Net Cash from Operating Activities $69.1M $60.3M $35.3M $43.8M $21.7M $26.6M $22.3M $28.8M
Investing Activities
Capital Expenditures $20.9M $14.6M $14.2M $9.6M $11.5M $8.9M $1.5M $7.8M
Business Acquisitions $468.0K $34.0M $42.5M $6.6M $39.3M $13.3M $4.0M $0
Net Cash from Investing Activities $-83.1M $-62.1M $-61.1M $-51.3M $-38.0M $-15.8M $-28.0M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $22.8M $25.1M $15.3M $19.6M $12.5M $6.9M $12.0M
Net Change in Cash $5.5M $22.3M $-10.8M $25.4M $-9.4M $987.0K $13.2M $13.0M
Free Cash Flow $48.2M $45.7M $21.1M $34.2M $10.1M $17.7M $20.8M $21.0M
← Newer Page 2 of 3 Older →